SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001654954-20-007820
Filing Date
2020-07-20
Accepted
2020-07-20 09:03:15
Documents
7
Period of Report
2020-07-16
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.08: Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT azrx8k.htm 8-K 77556
2 CERTIFICATE OF DESIGNATIONS SERIES B CONVERTIBLE PREFERRED ex3-1.htm EX-3 117739
3 FORM OF WARRANT ex4-1.htm EX-4 121049
4 FORM OF PURCHASE AGREEMENT ex10-1.htm EX-10 201403
5 FORM OF REGISTRATION RIGHTS AGREEMENT ex10-2.htm EX-10 92289
6 FIRST AMENDMENT TO 2014 OMNIBUS EQUITY INCENTIVE PLAN ex10-3.htm EX-10 14397
7 PRESS RELEASE ex99-1.htm EX-99 24564
  Complete submission text file 0001654954-20-007820.txt   650667
Mailing Address 760 PARKSIDE AVENUE SUITE 304 BROOKLYN NY 11226
Business Address 760 PARKSIDE AVENUE SUITE 304 BROOKLYN NY 11226 646-699-7855
AzurRx BioPharma, Inc. (Filer) CIK: 0001604191 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37853 | Film No.: 201035179
SIC: 2834 Pharmaceutical Preparations